What is ARWR's P/E ratio?

Arrowhead Pharmaceuticals Inc (ARWR) currently trades at a P/E ratio of 262.07.

Arrowhead Pharmaceuticals Inc reports a Return on Equity (ROE) of -49.01%.

What is ARWR's dividend yield?

Arrowhead Pharmaceuticals Inc offers a dividend yield of 0.00%.

What is ARWR's Quality Score?

Our AI rates ARWR's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy ARWR?

Our AI Timing Score for ARWR is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does ARWR belong to?

Arrowhead Pharmaceuticals Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Arrowhead Pharmaceuticals Inc (ARWR) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

ARWR AI Analysis Summary

Our AI summary for ARWR: Arrowhead Pharmaceuticals Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 262.07, ROE of -49.01%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

ARWR

Arrowhead Pharmaceuticals Inc

US:NASDAQ STOCK Healthcare >> Biotechnology News 79

USD 84.65

-2.67 (-3.06%) Day Change

Watchlist Portfolio Compare Chart

262.07

P/E

1.45

D/E

-49.0%

ROE

-13.3%

ROA

0.00%

Div Yield

ARROWHEAD PHARMACEUTICALS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 84.65 Price -2.67 (-3.06%) Day Change	NEWS SCORE: 79

ARWR, the overall quality is not good ( Quality = 46) but the timing to buy is ...(Sign In to See)...

Loading chart...

46 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROE is decreasing significantly
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

44%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	79
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	84.65
PBV / Sector	20.54 / 5.20
Earning Per Share	-2.07

PE / Sector	262.07 / 19.97
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	189.98 M GREAT
Average 1W Daily Value	151.91 M GREAT

Timing Factors

85%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

43%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

56%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-48.38 / 98.71
NPM Average (%) / Sector	-3,417.76 / -1,721.76
NPM Change Average (%) / Sector	11,029.66 / 5,211.62 GOOD
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-13.27 / 27.02
ROA Average (%) / Sector	-23.66 / -368.17
ROA Change Average (%) / Sector	2,792.29 / 5,404.12 GOOD
ROE (%) / Sector	-49.01 / 3.47
ROE Average (%) / Sector	-98.51 / 6.51
ROE Change Average (%) / Sector	3,550.69 / 2,128.13 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 07:59:29
Symbol	ARWR
Name	ARROWHEAD PHARMACEUTICALS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	140.86 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	12,299.64 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 177 East Colorado Boulevard, Pasadena, CA, United States, 91105

Phone: 626 304 3400

Website: https://arrowheadpharma.com

Employees: 711

Sector: Healthcare >> Biotechnology

Description: Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.